Adequacy of blood pressure control in high-risk hypertensive patients: The DEGREE study. (1st April 2022)

• Record Type: Journal Article
• Authors: Zeijen, Victor J.M.; Lafeber, Melvin; Versmissen, Jorie; Kroon, Abraham A.; Boersma, Eric; Daemen, Joost
• Is Part Of: International journal of cardiology. Volume 352(2022)
• Page Start: 137
• Page End: 143
• Publication Date: 2022-04-01
• Subjects: Antihypertensive agents -- Blood pressure monitoring -- Ambulatory -- Cardiovascular diseases -- Guideline -- Hypertension -- Prevalence; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2022.02.014
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Introduction: Hypertension is a modifiable risk factor in patients at the highest risk for cardiovascular events. New invasive treatment options are becoming available that might be particularly appealing for high-risk patients. Therefore, the aim of this study was to determine the prevalence of high-risk patients on routine therapy that do not meet guideline recommended ambulatory blood pressure (ABP) targets. Methods: This single-center, cross-sectional study was conducted at the Erasmus University Medical Center (Rotterdam, The Netherlands). Inclusion criteria were: (1) age 18–80 years, (2) drugs prescribed for hypertension or history of hypertension and (3) high cardiovascular risk as defined according to the European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines. Patients underwent standardized office blood pressure (OBP) and same-day 24-h ABP measurements. Blood pressure (BP) control was defined according to the 2018 ESC/ESH and 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Results: A total of 100 patients were enrolled (median age 71 years, 35% female). Mean OBP was 142.2/81.9 ± 18.6/12.6 mmHg and mean 24-h ABP was 126.1/70.1 ± 14.3/9.2 mmHg. Patients were on 2.0 [25th–75th percentile: 1.0–3.3] Defined Daily Doses of antihypertensive drugs. ESC/ESH guideline 24-h ABP and OBP targets were not met in 41.8% (95%CI: 31.5–52.6%) and 52.7% (95%CI: 42.0–63.3%), respectively. ACC/AHA guideline 24-h ABP and OBP targets were not met in 59.3% (95%CI: 48.5–69.5%) and 79.1% (95%CI: 69.3–86.9%), respectively. Conclusions: BP remains uncontrolled in 40–60% of high-risk hypertensive patients despite routine use of guideline-recommended therapy. Our findings support the search towards novel invasive BP lowering treatment options. Highlights: Hypertension is a modifiable risk factor in cardiovascular high-risk patients. Ambulatory blood pressure remains uncontrolled in 42–59% of high-risk patients. Office blood pressure remains uncontrolled in 53–79% of high-risk patients. Blood pressure control in high-risk patients remains suboptimal and could be improved. These patients could benefit from new (invasive) antihypertensive treatment modalities.